title: Prodrugs of pioglitazone for extended-release (XR) injectable formulations.
abstract: N-Acyloxymethyl derivatives of pioglitazone (PIO) have been prepared and characterized as model candidates for extended-release injectable formulations. All PIO derivatives prepared are crystalline solids as determined by powder X-ray diffraction, and the solubility in aqueous media is below 1 μM at 37 °C. The melting points steadily increase from 55 °C, for the hexanoyloxymethyl derivative, to 85 °C, for the palmitoyloxymethyl derivative; inversely, the solubilities in ethyl oleate decrease as a function of increasing acyl chain length. The butyroyloxymethyl ester has a higher melting point and a lower solubility in ethyl oleate than expected from the trend. The (13)C solid-state NMR spectra of the PIO homologues between the hexanoyloxymethyl derivative and stearoyloxymethyl derivative suggest a common structural motif with the acyl chains exchanging between two distinct conformations, and the rate of exchange is slower for longer chain derivatives. The butyroyloxymethyl derivative is efficiently converted to PIO in in vitro rat plasma with a half-life of <2 min at 37 (o) C, while the rate of enzymatic cleavage in rat plasma decreases as the ester chain length increases for the longer acyloxymethyl derivatives. The concentration of PIO in plasma increases rapidly, or "spikes," in the hours following intramuscular (IM) injection of either the HCl salt or the butyroyloxymethyl derivative. In contrast, the more lipophilic palmitoyloxymethyl derivative provides slow growth in the PIO concentration over the first day to reach levels that remain steady for 2 weeks. On the basis of its in vivo pharmacokinetic profile, as well as material and solubility properties, the PIO palmitoyloxymethyl derivative has potential as a once-monthly injectable medication to treat diabetes.
authors.affiliation: Alkermes plc , 852 Winter Street, Waltham, Massachusetts 02451-1420, United States.
authors.forename: Carlos N
authors.initials: CN
authors.lastname: Sanrame
authors.forename: Julius F
authors.initials: JF
authors.lastname: Remenar
authors.forename: Laura C
authors.initials: LC
authors.lastname: Blumberg
authors.forename: Julie
authors.initials: J
authors.lastname: Waters
authors.forename: Reginald L
authors.initials: RL
authors.lastname: Dean
authors.forename: Nan
authors.initials: N
authors.lastname: Dong
authors.forename: Kristi
authors.initials: K
authors.lastname: Kriksciukaite
authors.forename: Peixin
authors.initials: P
authors.lastname: Cao
authors.forename: Orn
authors.initials: O
authors.lastname: Almarsson
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical; D009682:Magnetic Resonance Spectroscopy; D000077205:Pioglitazone; D011355:Prodrugs / Q000737:chemistry*; D051381:Rats; D012995:Solubility; D045162:Thiazolidinediones / Q000737:chemistry*; D014961:X-Ray Diffraction
chemical_list: D011355:Prodrugs; D045162:Thiazolidinediones; D000077205:Pioglitazone
keywords: N-acyloxy derivatives; diabetes; extended-release; long acting injectable (LAI); pioglitazone prodrugs; prodrugs; solid-state NMR